WO2019230233A1 - Devil's-claw extract and variety of compositions containing same, and production method for devil's-claw extract - Google Patents

Abstract

The present invention addresses the problem of providing: a novel material having a beneficial effect on health and beauty, in particular, on whitening, anti-wrinkling of skin, anti-aging action, amelioration/improvement of arthrosis, etc.; and a method for producing such a material. The present invention solves the problem mentioned above by a devil's-claw extract that contains at least 1.0 wt% of harpagoside. In addition, in the devil's-claw extract, it is preferable for the content (in wt%) of harpagoside to be 0-1.0 with respect to the content (in wt%) of stachyose.

Description

Devil's claw extract, various compositions containing it, and method for producing devil's claw extract

The present invention relates to a devil's claw extract, various compositions containing it, and a method for producing the devil's claw extract. The present invention also relates to a composition for external use, a composition for internal use, and a food composition.

も People are always interested in health and beauty. Recently, whitening, anti-wrinkle, anti-aging cosmetics, functional foods, supplements and the like have attracted attention. In addition, air pollutants include PM2.5, yellow sand, exhaust gas, house dust, and various other fine particle substances. The effects on the circulatory organs such as the eyes, respiratory organs, and heart are well known. . Furthermore, in addition to diseases at these sites, air pollutants have also been known to cause skin diseases (skin disorders) such as atopy, allergies, and reduced barrier function. For this reason, cosmetics, functional foods, supplements, and the like that have effects such as anti-inflammation and improvement of skin roughness have attracted attention. Under such circumstances, there is a constant demand for new materials that have more excellent effects on whitening, anti-wrinkle, anti-aging, anti-inflammation, rough skin and the like.

On the other hand, Devil's Claw (Harpaphyphyum procumbens) is a sesame family perennial plant native to South Africa, and is called Devil's Claw because it can produce hard thorns, and it has long been used as a medicinal plant. As its action, anti-inflammatory action, antibacterial action, anti-inflammatory analgesic action and the like are known, and it has been traditionally used for antipyretic analgesia and treatment of indigestion. It is also known to be effective for prevention and symptom improvement of immune diseases such as knee osteoarthritis and rheumatism (see Non-Patent Documents 1 and 2, and Patent Documents 1 and 2). Furthermore, the Devil's Claw extract has an effect of improving rough skin, an exfoliation of skin, and a wrinkle improving effect, and an external preparation for skin utilizing the action has been disclosed (see Patent Document 3). As its active ingredient, the existence of iridoids such as harpagoside has been clarified. These active ingredients have various pharmacological effects, and may contain components that antagonize anti-inflammatory effects, and may have disadvantages such as restricted use depending on the route of administration, application site, and application target. (See Patent Documents 4 and 5 and Non-Patent Document 3). Furthermore, these components are also known as bittering agents (see Patent Document 6).

As an inhibitor of skin inflammation caused by atmospheric aerosol particles, a preparation containing an extract of the genus Hippophae as an active ingredient is known (see Patent Document 7). In addition, a skin care cosmetic containing a predetermined amount of magnesium aluminate metasilicate and octylmethoxycinnamate and / or hexyl diethylaminohydroxybenzoyl benzoate for the purpose of protection from air pollutants (see Patent Document 8) An anti-poration agent (see Patent Document 9) containing hyaluronic acid and / or a salt thereof as an active ingredient is known.

JP 2001-346545 A JP 2003-159030 A JP 2002-161043 A Special Table 2000-501113 JP 2002-2011136 A JP2015-528425A Japanese Unexamined Patent Publication No. 2016-216366 JP 2017-105825 A JP 2017-186276 A

The present invention has been made under such circumstances, and provides a novel material that exhibits excellent effects in health, beauty, especially whitening, anti-wrinkle, anti-aging, anti-inflammatory, and rough skin improvement. It is an object to provide a method for manufacturing such a material.

In the search for new materials that have beauty effects such as whitening, anti-wrinkle, anti-aging, arthropathy alleviation / improvement, health promotion effect, anti-inflammation, skin dryness, etc., Devils After examining various actions of the residue after removing harpagoside, which is one of the active ingredients of claw extract, it was found that various unexpected effects could be confirmed and utilized as a new material. The invention has been completed.

That is, the gist of the present invention is as follows.

[1] A devil's claw extract having a harpagoside content of 1.0% by weight or less.
[2] The devil's claw extract according to [1], wherein the content (% by weight) of harpagoside relative to the content (% by weight) of stachyose is 0 to 1.0.
[3] When the devil's claw extract is a dry powder, or when the devil's claw extract is a liquid, when it is a dry powder, the wavelength in the visible light region of an aqueous solution having a concentration of 0.5% by weight The Devil's Claw extract according to [1] or [2], wherein the absorbance at is 1 or less.
[4] A composition for suppressing melanin synthase gene expression, comprising the devil's claw extract according to any one of [1] to [3].
[5] A whitening composition comprising the devil's claw extract according to any one of [1] to [3].
[6] A composition for promoting collagen production, comprising the devil's claw extract according to any one of [1] to [3].
[7] A composition for promoting the formation of elastin fibers, comprising the devil's claw extract according to any one of [1] to [3].
[8] A composition for promoting hyaluronic acid production, comprising the devil's claw extract according to any one of [1] to [3].
[9] A composition for enhancing skin barrier function, comprising the devil's claw extract according to any one of [1] to [3].
[10] An anti-poration composition containing the devil's claw extract according to any one of [1] to [3].
[11] An anti-inflammatory composition for air pollutant-induced inflammation, comprising the devil's claw extract according to any one of [1] to [3].
[12] A composition for improving skin damage caused by air pollutants, comprising the devil's claw extract according to any one of [1] to [3].
[13] An anti-inflammatory composition for Gobi Kosa Dust-induced inflammation, comprising the devil's claw extract according to any one of [1] to [3].
[14] A composition for ameliorating / ameliorating arthropathy, comprising the devil's claw extract according to any one of [1] to [3].
[15] A composition for suppressing the expression of an inflammatory substance, comprising the devil's claw extract according to any one of [1] to [3].
[16] The composition according to [15], wherein the inflammatory substance is IL-1β, IL-6, or IL-8.
[17] A composition for external use containing the devil's claw extract according to any one of [1] to [3] or the composition according to any one of [4] to [16].
[18] A cosmetic containing the devil's claw extract according to any one of [1] to [3] or the composition according to any one of [4] to [13], [15], [16] Composition.
[19] An oral composition containing the devil's claw extract according to any one of [1] to [3] or the composition according to any one of [4] to [16].
[20] A food composition comprising the devil's claw extract according to any one of [1] to [3] or the composition according to any one of [4] to [16].
[21] Devil's claw extract according to any one of [1] to [3], or [6] to [8], [10], [11], [13], [15], [16] An ophthalmic composition containing the composition according to any one of the above.
[22] A devil's claw extract comprising the steps of (A) obtaining an extract of devil's claw dry powder and (B) treating the extract with a resin that adsorbs a hydrophobic component to obtain a purified extract. Manufacturing method.
[23] Manufactured by a production method comprising a step of obtaining an extract of (A) a devil's claw dry powder, and (B) treating the extract with a resin that adsorbs a hydrophobic component to obtain a purified extract. The devil's claw extract according to any one of [1] to [3].

The devil's claw extract of the present invention is obtained by removing a hydrophobic substance such as harpagoside known as an active ingredient from the conventional devil's claw extract, and the content of harpagoside is 1.0% by weight or less. It is a novel extract that is remarkably suppressed. Unlike the conventional devil's claw extract, there is an advantage that it is easy to mix in various products because it has excellent stability and high solubility because it does not produce unique coloring, odor and bitterness. In addition, it can be expected that the occurrence of inconvenient events depending on the administration route, application site, and application target is suppressed. Furthermore, this devil's claw extract of the present invention is a melanin synthase gene expression inhibitory action in skin, collagen production promoting action, elastin fiber formation promoting action, hyaluronic acid production promoting action, an inflammatory substance induced by air pollutants. Has the effect of suppressing production, improving the skin damage induced by air pollutants (including the decrease in barrier function), whitening, anti-wrinkle, anti-aging, alleviation / improvement of arthropathy, anti-inflammatory effect (anti Resolution) and skin barrier function enhancement effect can also be expected. From the above, the devil's claw extract of the present invention is used as cosmetics, pharmaceuticals, quasi drugs, foods (functional foods, supplements, drinks, etc.), etc. It can be suitably used as an ophthalmic composition.

It is a figure which shows the result of the coloring evaluation in the visible region of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a figure which shows the result of the coloring evaluation in the visible region of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a photograph of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a figure which shows the result of the thermal stability evaluation (coloring change evaluation) of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a figure which shows the transmittance | permeability of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a figure which shows the result of the odor test of the aqueous solution of the conventional product and the devil's claw extract of this invention. It is a figure which shows the melanin synthase gene (Tyrosinase, TYR) expression inhibitory effect of the devil's claw extract of this invention. It is a figure which shows the melanin synthase gene (Tyrosinase related protein 1, TYRP1) expression inhibitory effect of the devil's claw extract of this invention. It is a figure which shows the melanin synthase gene (Dopachrome tautomerase, DCT) expression inhibitory effect of the devil's claw extract of this invention. It is a figure which shows the temporal analysis result of the melanin synthase gene (Dopachrome tautomerase, DCT) expression inhibitory effect of the devil's claw extract of this invention. It is a figure which shows the collagen production promotion effect in the normal human skin fibroblast (NHDF) of the devil's claw extract of this invention. It is a figure which shows the collagen production promotion effect in the normal human skin fibroblast (NHDF) of stachyose. It is a figure which shows the collagen production promotion effect in the normal human skin fibroblast (NHDF) of sucrose. It is a figure which shows the collagen production promotion effect in the normal human skin fibroblast (NHDF) of raffinose. It is a figure which shows the elastin fiber formation promotion effect in the normal human skin fibroblast (NHDF) of the devil's claw extract of this invention. It is a figure which shows the hyaluronic acid production promotion effect in the rabbit-derived cartilage culture cell of the devil's claw extract of this invention. It is a figure which shows the hyaluronic acid production promotion effect in the normal human skin fibroblast (NHDF) of the devil's claw extract of this invention. It is a figure which shows the inhibitory effect of Gobi Kosa Dust induced inflammatory cytokine production in normal human epidermal cells (NHEK) of the devil's claw extract of the present invention. It is a figure which shows the inhibitory effect of Gobi Kosa Dust induced inflammatory cytokine production in human corneal epithelial cells (HCET) of the devil's claw extract of the present invention.

Hereinafter, the present invention will be described in detail. In addition, the term used in this specification is interpreted by the meaning normally used in the said technical field unless there is particular mention.

[Devil's Claw Extract]
The devil's claw extract of the present invention is obtained by removing a hydrophobic substance such as harpagoside known as an active ingredient from a conventional devil's claw extract using a resin or the like, and the content of harpagoside is 1 It is a novel extract characterized by being not more than 0.0% by weight.

Devil's Claw (Harpagophytum procumbens) is a sesame perennial plant native to South Africa, and its tubers have long been used as medicinal plants. This devil's claw is rich in harpagoside, an iridoid glycoside known to have anti-inflammatory and analgesic effects. Further, it is known that various components such as polyphenols, cinnamic acid, polysaccharides and the like are contained.

(Content components)
Since the devil's claw extract of the present invention is obtained by removing a hydrophobic substance using a resin or the like as described above, the content of harpagoside is 1.0% by weight or less. In the devil's claw extract of the present invention, from the viewpoint of stability, degree of coloring, and odor, the content of harpagoside is preferably small, preferably 0.5% by weight or less, and 0.3% by weight. More preferably, it is more preferably 0.1% by weight or less, and particularly preferably 0.05% by weight or less. That is, the content of harpagoside in the devil's claw extract of the present invention is 0 to 1.0% by weight, preferably 0 to 0.5% by weight, and preferably 0 to 0.3% by weight. More preferably, it is 0 to 0.1% by weight, further preferably 0 to 0.05% by weight. The content of harpagoside can be quantified by analysis using HPLC.

The devil's claw extract of the present invention may contain polysaccharides such as harpagide, stachyose, sucrose, and raffinose, polyphenols such as anthocyanin, cinnamic acid, and the like as components other than harpagoside. Since the devil's claw extract of the present invention adsorbs and removes hydrophobic components with a resin or the like, the content of the above polyphenols tends to be smaller than that of the conventional devil's claw extract. The polyphenol content in the devil's claw extract of the present invention is 2% by weight or less, preferably 1.8% by weight or less, more preferably 1.5% by weight or less, and 1.0% by weight. More preferably, it is% or less. That is, the polyphenol content in the devil's claw extract of the present invention is 0 to 2.0% by weight, preferably 0 to 1.8% by weight, and preferably 0 to 1.5% by weight. More preferably, it is 0 to 1.0% by weight. The content of polyphenol can be quantified by analysis using a spectrophotometer.

The content of the stachyose in the devil's claw extract of the present invention is 50% by weight or more, preferably 55% by weight or more, more preferably 60% by weight or more, and 65% by weight or more. More preferably.

The ratio of the content (wt%) of harpagoside to the content (wt%) of stachyose in the devil's claw extract of the present invention, that is, the value of the content (wt%) of harpagoside / content (wt%) of stachyose is 0 to 0.02, preferably 0 to 0.01, more preferably 0 to 0.005, still more preferably 0 to 0.003, and 0 to 0.001. It is particularly preferred. When the ratio of the content of halpagoside (% by weight) to the content of stachyose (% by weight) is within the above range, the devil's claw extract of the present invention is excellent in stability because it is difficult for coloring and odor to occur, Since solubility becomes high, it becomes easy to mix | blend with various products.

The devil's claw extract of the present invention may be a liquid, or the liquid may be made into a dry powder by spray drying. When the devil's claw extract of the present invention is a liquid, an extraction solvent may be contained. Examples of the extraction solvent include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, ethyl ether, propyl ether, and the like. Polar organic solvents such as ethers, esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these may be selected and used. Among organic solvents, ethanol that can be used safely in cosmetics, pharmaceuticals, food production and the like and is easily soluble in water is preferable, or a combination thereof may be used. In addition, the devil's claw extract of the present invention may be a solution obtained by concentrating and drying the above extract solution in a polar solvent or dissolving a dry powder by spray drying.

When the devil's claw extract of the present invention is a dry powder, powdered base materials such as dextrin added in the process of dry powdering, proteins such as casein soda, whey, gelatin, milk, egg white, sucrose, lactose, etc. Oligosaccharides, gum arabic, starch or degradation products thereof may be contained.

(Characteristic)
The pH of the devil's claw extract of the present invention is usually from 2.0 to 10.0, preferably from 3.0 to 9.0, more preferably from 4.0 to 8.0. More preferably, it is 0.0 to 7.5.

</ RTI> The devil's claw extract of the present invention is characterized in that coloring is remarkably suppressed as compared with the conventional devil's claw extract. Specifically, when the devil's claw extract of the present invention is a dry powder, or when the devil's claw extract is a liquid, when it is a dry powder, Absorbance at a wavelength in the visible light region is 0.1 or less. The visible light region means a wavelength of 400 nm to 500 nm. The absorbance is preferably 0.08 or less, more preferably 0.05 or less, and further preferably 0.03 or less.

Furthermore, the devil's claw extract of the present invention is significantly less stable in color change after long-term storage and excellent in stability than the conventional devil's claw extract. Therefore, the devil's claw extract of the present invention can extend the storage period as a raw material or a product containing it.

The devil's claw extract of the present invention has significantly reduced odors peculiar to harpagoside compared to the conventional devil's claw extract. Specifically, it can be confirmed by performing a sensory test using purified water as a negative control.

Since the devil's claw extract of the present invention has higher solubility in a water-soluble solvent than the conventional devil's claw extract, the permeability is the same as that of purified water, and the transparency is excellent. Therefore, it can be used for various products such as cosmetics and beverages.

(Function and effect)
The devil's claw extract of the present invention has an action of suppressing the expression of intracellular melanin synthase gene. Examples of the melanin synthase gene include TYR (Tyrosinase, TYR), TYRP1 (Tyrosinase related protein 1), DCT (Dopachrome tautomerase), and the like. When the devil's claw extract of the present invention is allowed to act on cells such as melanocytes, the expression of the melanin synthase gene can be suppressed. Therefore, the devil's claw extract of the present invention has a whitening effect and can improve sunburn and aging due to aging. That is, the devil's claw extract of the present invention can be suitably used as a composition for suppressing melanin synthase gene expression, a melanin synthase gene expression inhibitor, a composition for whitening, and a whitening agent.

The devil's claw extract of the present invention has an action of improving collagen production ability of various cells such as fibroblasts, that is, an action of promoting collagen production. The collagen production promoting action may be obtained by combining the effects of polysaccharides such as sucrose, stachyose and raffinose contained in the devil's claw extract of the present invention. The devil's claw extract of the present invention is an anti-wrinkle and anti-aging material that exhibits an excellent effect on wrinkles and sagging by promoting collagen production from cells, and a composition for promoting collagen production, promoting collagen production As an agent, it can be suitably used in various products.

The devil's claw extract of the present invention has an effect of promoting the formation of elastin fibers by various cells such as fibroblasts. The devil's claw extract of the present invention can be suitably used in various products as an anti-wrinkle and anti-aging material having an effect on wrinkles and sagging, as an elastin fiber formation promoting composition, and an elastin fiber formation promoting agent. .

The devil's claw extract of the present invention has an action of improving the hyaluronic acid production ability of various cells such as fibroblasts and chondrocytes, that is, an action of promoting hyaluronic acid production. The devil's claw extract of the present invention can be suitably used as an anti-wrinkle and anti-aging material that exhibits an excellent effect on wrinkles and sagging by promoting hyaluronic acid production from cells. In addition, one of the causes of joint pain associated with aging is a decrease in joint components such as hyaluronic acid, but the effect of weakening joint pain is expected by ingesting the devil's claw extract of the present invention. The devil's claw extract of the present invention can be suitably used in various products as a hyaluronic acid production promoting composition and a hyaluronic acid production promoting agent.

The devil's claw extract of the present invention has an inhibitory effect on the production of inflammatory substances induced by air pollutants. That is, the devil's claw extract of the present invention is inflammatory from various cells such as (human normal skin) epidermal cells and (human) corneal epithelial cells induced by air pollutants such as Gobi Kosa Dust and PM2.5. Has the effect of suppressing the production of substances. Therefore, the devil's claw extract of the present invention is an anti-inflammatory composition, particularly an anti-inflammatory composition for inflammation induced by air pollutants, and an improvement for skin disorders (including reduced barrier function) induced by air pollutants. The composition, composition for enhancing skin barrier function, and anti-poration composition can be suitably used in various products.

[Devil's Claw Extract Manufacturing Method]
The method for producing a devil's claw extract of the present invention comprises (A) a step of obtaining an extract of devil's claw dry powder, and (B) treating the extract with a resin that adsorbs a hydrophobic component to obtain a purified extract. A obtaining step. Furthermore, you may have (C) powdering process and (D) powder re-dissolution process. Each step will be described in detail below.

(A) The process of obtaining the extract liquid of devil's claw dry powder The dried material of the devil's claw tuber part is cut and ground with a mixer etc. if necessary. This is extracted with an extraction solvent. Examples of the extraction solvent include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, ethyl ether, propyl ether, and the like. Polar organic solvents such as ethers, esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these may be selected and used. Among organic solvents, ethanol that can be used safely in cosmetics, pharmaceuticals, food production and the like and is easily soluble in water is preferable, or a combination thereof may be used, for example, 30% to 70% (W / W) An aqueous ethanol solution and a 50% (W / W) aqueous ethanol solution can be more preferably used.

The temperature at the time of the extraction is not particularly limited, but heating extraction is preferable from the viewpoint of improving extraction efficiency. The heating temperature is preferably 40 ° C. to 100 ° C., more preferably 50 ° C. to 90 ° C. The extraction time can be appropriately changed depending on the temperature at the time of extraction, but in the case of heat extraction, it is usually 0.5 to 48 hours, preferably 1 to 15 hours, more preferably 1.5 to 10 hours. In the case of normal temperature extraction, it is usually 2 to 20 days, preferably 5 to 15 days, more preferably 8 to 12 days. During extraction, the efficiency of extraction can be improved by stirring. After extraction, treatment with activated carbon or the like may be performed. Thereafter, it is filtered through a filter paper or the like to obtain an extract.

(B) The process which processes the said extract with the resin which adsorb | sucks a hydrophobic component, and obtains a refined extract In this process, the said extract is column-purified and a refined extract is acquired. As said column, the column comprised from resin which can adsorb | suck hydrophobic components, such as a harpagoside, can be used. Such a resin is not particularly limited as long as it can adsorb a hydrophobic component. For example, Diaion (registered trademark) HP20, HP21, HP20SS; Sepabeads (registered trademark) SP825L, SP850, SP700, Examples thereof include aromatic synthetic adsorbents such as SP70, SP207, SP207SS, and SP20SS, and methacrylic synthetic adsorbents such as Diaion (registered trademark) HP2MGL and HP2MGS (all manufactured by Mitsubishi Chemical Corporation). The purification in this step may be batch purification using the above resin. Purification using a column composed of the above resin and batch purification can be performed according to specifications and the like by a method suitable for each resin. By this step, a purified extract from which part or all of the hydrophobic component has been removed from the extract obtained in the step (A) can be obtained.

(C) Powdering step In this step, the purified extract obtained in step (B) is used as powder. Examples of the method for turning the purified extract into a powder include a freeze-drying method, a spray-drying method, and a concentration / drying method.

(D) Powder redissolving step In this step, the powder obtained in step (C) is dissolved again in a solvent. Examples of the solvent include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, and ethers such as ethyl ether and propyl ether. , Polar organic solvents such as esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone may be used, and one or more of these may be selected and used. Of these, 1,3-butylene glycol, propylene glycol, dipropylene glycol and the like are preferable, and 1,3-butylene glycol is more preferable.

The devil's claw extract of the present invention obtained by the production method of the present invention is subjected to the above steps to remove hydrophobic substances such as harpagoside known as active ingredients from the conventional devil's claw extract. By combining the effects of the respective components appropriately, the various effects described above can be achieved.

In addition to the anti-inflammatory analgesic effect, the devil's claw extract obtained by the above step (A) is capable of suppressing melanin synthase gene expression in the skin, promoting collagen production, promoting elastin fiber formation, promoting hyaluronic acid production, air Has the effect of suppressing the production of inflammatory substances (IL-6, IL-8, etc.) induced by pollutants, and the effect of improving skin disorders (including reduced barrier function) induced by air pollutants. Anti-aging effects such as wrinkles, anti-aging, arthropathy, and anti-inflammatory effects can also be expected. The devil's claw extract obtained by the step (A) is also used as cosmetics, pharmaceuticals, quasi-drugs (functional foods, supplements, drinks, etc.), etc., and as a form, although there are problems such as coloring. It can be used as a composition, oral composition (including food composition), ophthalmic composition and the like. In addition, since the devil's claw extract obtained by the said (A) process contains iridoids, such as a harpagoside which has a bitter taste and is known to have various pharmacological effects, administration route, application site Depending on the application target, there may be inconveniences.

[Various compositions and agents containing devil's claw extract]
As described above, since the devil's claw extract of the present invention has an inhibitory action on melanin synthase gene expression, the composition containing the devil's claw extract of the present invention is a composition for suppressing melanin synthase gene expression, melanin synthesis It can be used as an enzyme gene expression inhibitor, a whitening composition, and a whitening agent. The present invention also includes a composition for suppressing melanin synthase gene expression, a melanin synthase gene expression inhibitor, a composition for whitening, and a whitening agent containing the devil's claw extract of the present invention.

As described above, since the devil's claw extract of the present invention has a collagen production promoting action on various cells, the composition containing the devil's claw extract of the present invention is a composition for promoting collagen production, collagen production. Can be used as an accelerator. This invention also contains the composition for collagen production promotion containing the devil's claw extract of this invention, and a collagen production promoter.

As described above, since the devil's claw extract of the present invention has an elastin fiber formation promoting action on fibroblasts and the like, the composition containing the devil's claw extract of the present invention is a composition for promoting elastin fiber formation. Can be used as an elastin fiber formation promoter. The present invention also includes an elastin fiber formation promoting composition and an elastin fiber formation promoter containing the devil's claw extract of the present invention.

As described above, since the devil's claw extract of the present invention has a hyaluronic acid production promoting action of various cells, the composition containing the devil's claw extract of the present invention is a composition for promoting hyaluronic acid production, hyaluronic acid production Can be used as an accelerator. It can also be used as a composition for reducing or improving arthropathy. The present invention also includes a hyaluronic acid production promoting composition, a hyaluronic acid production promoting composition, and an arthropathy alleviating / ameliorating composition containing the devil's claw extract of the present invention.

As described above, the devil's claw extract of the present invention has an inhibitory effect on the production of inflammatory substances induced by air pollutants. That is, the devil's claw extract of the present invention is inflammatory from various cells such as (human normal skin) epidermal cells and (human) corneal epithelial cells induced by air pollutants such as Gobi Kosa Dust and PM2.5. Since it has an action of suppressing the production of substances (IL-1β, IL-6, IL-8, etc.), the present invention provides an anti-inflammatory composition containing the devil's claw extract of the present invention, particularly an air pollutant Anti-inflammatory composition for inflammation induced by air, composition for improving skin damage (including reduced barrier function) due to air pollutants, composition for enhancing skin barrier function, and anti-poration composition.

Composition for inhibiting melanin synthase gene expression, melanin synthase gene expression inhibitor, whitening composition, whitening agent, composition for promoting collagen production, collagen production promoter, elastin fiber containing devilsclaw extract of the present invention Composition promoting composition, elastin fiber formation promoter, hyaluronic acid production promoting composition, hyaluronic acid production promoting agent, anti-inflammatory composition, anti-inflammatory agent, skin barrier function enhancing composition, skin barrier function enhancing agent , Anti-pollution composition, anti-pollution agent, anti-inflammatory composition for air pollutant-induced inflammation, anti-inflammatory agent for air pollutant-induced inflammation, composition for improving skin damage by air pollutant, skin disorder by air pollutant Improvement agent, anti-inflammatory composition for Gobi Kosa Dust-induced inflammation, Gobi Kosa Dust-induced inflammation Anti-inflammatory agent, arthropathy alleviation / amelioration composition, arthritis alleviation / amelioration agent, inflammatory substance expression suppression composition, inflammatory substance expression inhibitor, IL-1β, IL-6 or IL-8 expression A composition such as an inhibitory composition, IL-1β, IL-6 or IL-8 expression inhibitor can be applied to various forms such as externally or internally. That is, the above-mentioned various compositions and various agents may be compositions for external use, oral compositions such as compositions for internal use and food compositions (including eye care supplements), eye drops and eye cleansing agents. It may be an ophthalmic composition such as an eye ointment. Specifically, pharmaceuticals, quasi-drugs, topical (hands, feet, knees, elbows, heels, faces, around the eyes, etc.) or systemic skin cosmetics and skin cleansing agents, medicinal products applied to the scalp / hair Various external preparations for skin including cosmetic preparations, bath preparations, compositions for internal use of drugs and quasi-drugs to be taken orally, drugs and quasi-drugs by eye drops (including eye wash and eye ointment) ), General food and drink, supplements and drinks, and functional foods.

The content of the devil's claw extract in the various compositions and various agents containing the devil's claw extract of the present invention may be appropriately adjusted depending on the dosage form and use, and is not particularly limited. In terms of the amount of stachyose contained in the claw extract, it is 0.00001 wt% to 10 wt%, preferably 0.00005 wt% to 5 wt%, and 0.0001 to 2 wt%. More preferably, it is 0.0005 to 2% by weight.

The above-mentioned various compositions and various agents containing the devil's claw extract of the present invention may contain other components in addition to the essential component of the devil's claw extract as long as the effects of the present invention are not impaired. For example, a combination that can be used in combination with a drug or the like that is used in normal treatment for external or internal use, and the combination of which the effect of the present invention is more easily exhibited by the combined drug is preferable.

Examples of these other components include anti-inflammatory agents (excluding the devil's claw extract of the present invention), cooling agents, antibacterial / bactericidal agents, vitamins, organic acids, sugars, moisturizing ingredients, polyhydric alcohols, scrubs. Agent, ultraviolet absorbing component, ultraviolet scattering component, astringent component, peptide or derivative thereof, amino acid or derivative thereof, washing component, keratin softening component, cell activation component, anti-aging component, anti-glycation component, blood circulation promoting component, whitening component , A decongestant component, an eye muscle modifier component, an antihistamine component or an antiallergic component, polyphenols, and the like. In addition, in the said various compositions and various agents of this invention, these components may be used individually by 1 type, respectively, and may use 2 or more types together, respectively.

Examples of the anti-inflammatory agent include plants (for example, comfrey, auren, dokudami, chamomile, bilberry, izayoibara, enmeiso, loquat, bitter mint, glyceryl glucoside, royal jelly, melia azilacta, mallow algae, oxon, peonies, chimpi) Derived from, allantoin and derivatives thereof, glycyrrhetinic acid and derivatives thereof, glycyrrhizic acid and derivatives thereof, salicylic acid derivatives, aminocaproic acid, azulene and derivatives thereof, zinc oxide, calamine, tranexamic acid, ufenamate, bufexamac, ibuprofen piconol, hydrochloric acid Examples include pyridoxine, menthol, camphor, turpentine oil, indomethacin, azelaic acid, tocopherol acetate, hydrocortisone, prednisolone and their salts. It is. Among them, a combination of allantoin, glycyrrhetinic acid, dipotassium glycyrrhizinate, aminocaproic acid, azulene and derivatives thereof, tocopherol acetate, tranexamic acid, bilberry leaf extract, chimpi extract, Izayoi rose extract, mallow flower extract and dokudami extract is preferable.

Examples of the refreshing agent include mentols and derivatives thereof, camphor, borneol, geraniol, cineol, anethole, limonene, eugenol, and other terpenes (these may be d-form, l-form or dl-form); And essential oils such as oil, bergamot oil, peppermint oil, cool mint oil, spearmint oil, fennel oil, mint oil, cinnamon oil, rose oil and turpentine oil. Of these, combinations with menthol and derivatives thereof, camphor, eucalyptus oil, peppermint oil, and peppermint oil are particularly preferred.

Examples of the antibacterial / bactericidal agent include isopropylmethylphenol, chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, ethanol, benzethonium chloride, cresol, gluconic acid and its derivatives, popidone iodine, potassium iodide, iodine, triclocarban, triclosan Photosensitive element 101, photosensitive element 201, paraben, phenoxyethanol, alkanediol having 5 to 10 carbon atoms (for example, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol, etc.), hydrochloric acid Alkyldiaminoglycine, pyroctoolamine, miconazole or its salt, cetyltrimethylammonium chloride, zinc pyrithione, cetylpyridinium chloride, miconazole, chlorobutanol, ethylhexylglycyl Phosphorus, butyl carbamate propynyl iodide, capryl hydroxamic acid, phenethyl alcohol, benzyl alcohol, methylisothiazolinone, sorbic acid, potassium sorbate, β-glycyrrhetinic acid, azelaic acid, polydronium chloride, sodium benzoate, chlorhexidine gluconate, Examples include components derived from sodium dehydroacetate, alkyl paraoxybenzoate, oxyquinoline sulfate, biguanide compounds, plants (for example, aloe, clara, rosemary, mulberry, eucalyptus, kina, clove). Among them, isopropylmethylphenol, salicylic acid, benzalkonium chloride, ethanol, gluconic acid, paraben, phenoxyethanol, 1,2-pentanediol, 1,2-hexanediol, azelaic acid, ethylhexylglycerin, propynyl iodide butylcarbamate, capryl A combination with hydroxamic acid, rosemary extract, eucalyptus extract, aloe extract, quina extract is preferred.

The vitamins may be water-soluble vitamins or oil-soluble vitamins. For example, pyridoxine, pyridoxal, pyridoxamine, 5′-phosphate pyridoxal, and salts thereof (for example, pyridoxine hydrochloride, pyridoxine acetate, hydrochloric acid) Vitamin B6 such as pyridoxal, pyridoxamine hydrochloride); pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-panthecin, D-panthetin, coenzyme A, pantothenyl ethyl ether, and salts thereof Pantothenic acids; nicotinic acid, dl-α-tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, 1- (4-methylphenyl) ethyl nicotinate, nicotinamide, and salts thereof Nico Chitin acids; γ-oryzanol, thiamine, dibenzoyl thiamine, thiamine cetyl, thiamine monophosphate, thiamine diphosphate, thiamine triphosphate, and salts thereof (eg, dibenzoyl thiamine hydrochloride, thiamine hydrochloride, thiamine cetyl Hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate phosphate, thiamin diphosphate hydrochloride, thiamine triphosphate monophosphorus Vitamin B1 such as acid salt); riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5′-phosphate ester Vitamin B2 such as lithium, riboflavin tetranicotinate, and salts thereof; biotins such as biotin, biocytin, and salts thereof; folic acids such as folic acid, pteroylglutamic acid, and salts thereof; cyanocobalamin, hydroxocobalamin , Deoxyadenosylcobalamin, and salts thereof such as vitamin B12; ascorbic acid, sodium ascorbate, dehydroascorbic acid, ascorbic acid phosphate, ascorbic acid sulfate, ascorbic acid-2-glucoside, 2-O-ethyl Ascorbic acid, 3-O-ethylascorbic acid, glyceryl ascorbic acid, bisglyceryl ascorbic acid, ascorbic acid derivatives such as alkylglyceryl ascorbic acid, and salts thereof (for example, sodium ascorbate) Water-soluble vitamin C such as sodium, sodium ascorbate phosphate, magnesium ascorbate phosphate, ascorbyl stearate, disodium isostearyl ascorbyl phosphate, L-ascorbyl dipalmitate, ascorbyl tetraisopalmitate ( Ascorbyl tetra-2-hexyldecanoate), oil-soluble or amphiphilic vitamin C such as trisodium ascorbyl palmitate; δ-tocopherol, dl-α-tocopherol, dl-α-tocopherol acetate, dl-α succinate -Tocopherol, dl-α-tocopherol calcium succinate, tocopherol linoleate, (linoleic acid / oleic acid) tocopherol, tocopherol, (ascorbyl / tocopheryl) potassium phosphate, male Vitamin E such as ascorbyl tocopheryl acid; oil-soluble vitamin C such as ascorbigen-A, ascorbyl stearate, ascorbyl palmitate, L-ascorbyl dipalmitate, ascorbyl tetra-2-hexyldecanoate, and salts thereof Vitamin D such as ergocalciferol and cholecalciferol; vitamin K such as phylloquinone and farnoquinone; retinol, retinal, retinoic acid, 3-dehydroretinol, 3-dehydroretinal, 3-dehydroretinoic acid, hydrogenated retinol, etc. Vitamin A and its derivatives, retinol palmitate, retinol propionate, retinol linoleate, retinol acetate, retinol retinoate, d-δ-tocopheryl retinoate, α-toco Vitamin A derivatives such as ferryl retinoate and β-tocopheryl retinoate, provitamins A such as α-carotene, β-carotene, γ-carotene, cryptoxanthine, lycopene, zeaxanthin, echinone; ferulic acid, pyrroloquinoline quinone Alternatively, salts thereof, hesperidin derivatives such as hesperidin and glucosylherperidine, ubiquinone, glucurolactone, glucuronic acid amide, orotic acid, L-carnitine, α-lipoic acid, orotic acid, and other vitamin-like agents are mentioned. Of these, combinations with vitamins B, vitamins C, vitamins E, vitamins A, and vitamin-like agents are preferred. Particularly, pyridoxine hydrochloride, pantothenyl alcohol (panthenol), nicotinamide, riboflavin, cyanocobalamin, ascorbic acid, Ascorbic acid phosphate, Ascorbic acid-2-glucoside, 3-O-ethylascorbine, sodium ascorbate, sodium ascorbate phosphate, magnesium ascorbate phosphate, acetic acid dl-α-tocopherol, ascorbyl palmitate Ascorbyl tetra-2-hexyldecanoate, retinol, retinol palmitate, retinol propionate, retinol acetate, pyrroloquinoline quinone or salt thereof, ubiquinone, γ-oryza The combination with 1 type, or 2 or more types chosen from Nord is more preferable.

Examples of the organic acid include gluconic acid, aspartic acid, aminoethylsulfonic acid, citric acid, glutamic acid, succinic acid, oxalic acid, fumaric acid, malonic acid, maleic acid, propionic acid, malic acid, salicylic acid, glycolic acid, Examples include phytic acid, tartaric acid, acetic acid, lactic acid, pantothenic acid, glycyrrhetinic acid, alginic acid, ascorbic acid, benzoic acid, adipic acid, glutamic acid, azelaic acid, and salts thereof. Examples of the salt include salts of mineral acids such as sulfuric acid, hydrochloric acid or phosphoric acid, salts of organic acids such as maleic acid or methanesulfonic acid, alkali metal salts such as sodium or potassium, alkaline earth metal salts, zinc, copper , Ammonium salts, basic amino acid salts, amine salts such as triethanolamine, and the like. Preferably, it is preferably selected from alkali metal salts, alkaline earth metal salts, amine salts, zinc, and copper, and sodium, potassium, triethanolamine salts, zinc, and copper are more preferable. Among these, a combination of one or more selected from gluconic acid, citric acid, glutamic acid, succinic acid, malic acid, salicylic acid, glycolic acid, phytic acid, tartaric acid, lactic acid, and glycyrrhetinic acid is more preferable.

Examples of the saccharide include monosaccharides and disaccharides, specifically glucose, maltose, trehalose, sucrose, cyclodextrin, xylitol, sorbitol, mannitol and the like.

Examples of the moisturizing component include diglycerin trehalose, glycosyl trehalose, trehalose; hyaluronic acids such as hyaluronic acid, acetyl hyaluronic acid, and low molecular hyaluronic acid, or salts thereof (salts such as sodium, potassium, and zinc) or derivatives thereof, heparin Similar substances, mucopolysaccharides such as sodium chondroitin sulfate; MPC polymers; collagen, elastin, keratin, chitin, chitosan, etc. and their hydrolysates; amino acids such as glycine, aspartic acid, arginine; sodium lactate, urea, pyrrolidone carboxylic acid Natural moisturizing factors such as sodium; lipids such as ceramide, glucosylceramide, cholesterol, phytosterol, cholesterol derivatives, phytosterol derivatives, phospholipids; chamomile extract, hamamelis extract, chi Extracts, perilla extracts, grapefruit extracts and other plant extract extracts; multivalents such as glycerin, PPG-17 butes-17, PPG-25 sorbitol, polyoxyalkylene alkyl glucoside, PEG / PPG / polybutylene glycol-8 / 5/3 glycerin Examples include alcohols or derivatives thereof; sugar alcohols such as sorbitol, xylitol, erythritol, maltose-sucrose condensate (glucooligosaccharide), hydrolyzed xylan (xylooligosaccharide); and hydroxyethylurea. Among them, hyaluronic acid, low molecular weight hyaluronic acid, sodium hyaluronate, sodium acetyl hyaluronate, zinc hyaluronate, sodium lactate, heparin analog, urea, sodium pyrrolidonecarboxylate, trimethylglycine, MPC polymer, hydrolyzed collagen, hydrolyzed elastin, A combination with one or more selected from collagen, ceramide, hydrogenated lecithin phospholipid, chamomile extract, grapefruit extract, polyhydric alcohol, polyoxypropylene methyl glucoside, and hydroxyethyl urea is more preferable.

The polyhydric alcohol is preferably one having 2 to 10 carbon atoms, such as glycerin, diglycerin, triglycerin, propylene glycol, dipropylene glycol, 1,3-butanediol, ethylene glycol, diethylene glycol, isoprene glycol, 1 3-butylene glycol, sorbitol, xylitol, erythritol, mannitol, pentanediol, hexanediol, octanediol, decanediol, neopentylglycol, 1,3-propanediol, and the like. Of these, a combination of one or more selected from glycerin, diglycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, sorbitol, pentanediol, hexanediol, and octanediol is more preferable.

Examples of the scrub agent include apricot kernel powder, almond shell powder, apricot kernel powder, sodium chloride grain, olive kernel powder, dried sea water grain, candelilla wax, walnut shell powder, cherry core powder, coral powder, charcoal powder. , Hull paste powder, polyethylene powder, silicic anhydride and the like.

Examples of the ultraviolet absorbing component include octyl triazone, dimethoxybenzylidene dioxoimidazolidine propionate octyl, 2-methoxyhexyl paramethoxycinnamate, phenylbenzimidazole sulfonic acid, diethylaminohydroxybenzoylbenzoic acid hexyl ester, bisethylhexyloxyphenol Examples include methoxyphenyltriazine, t-butylmethoxydibenzoylmethane, paraaminobenzoic acid and its derivatives, octylparadimethylaminobenzoate, dihydroxybenzophenone, methylenebisbenzotriazolyltetramethylbutylphenol and the like. Among them, paramethoxycinnamic acid 2-ethylhexyl, diethylaminohydroxybenzoyl benzoic acid hexyl ester, octyl triazone, bisethylhexyloxyphenol methoxyphenyltriazine, t-butylmethoxydibenzoylmethane, methylenebisbenzotriazolyltetramethylbutylphenol The combination with 1 type or 2 types or more is more preferable.

Examples of the ultraviolet scattering component include hydrous silicic acid, zinc silicate, cerium silicate, titanium silicate, zirconium oxide, cerium oxide, titanium oxide, zinc oxide, iron oxide, and anhydrous silicic acid, and the like. Inorganic compounds coated with inorganic powders such as hydrous silicic acid, aluminum hydroxide, mica and talc, or compounded with resin powders such as polyamide, polyethylene, polyester, polystyrene, nylon, silicone oil and fatty acid aluminum What was processed with salt etc. is mentioned.

Examples of the astringent components include, for example, metal salts such as ethanol, zinc sulfate, aluminum chloride, and zinc sulfocolate, organic acids such as tannic acid, plants (for example, seaweed, thyme, black tea, oolong tea, green tea, hypericum, hamelis, loquat, Ingredients derived from buttonpi, saxifrage, rooibos, forsythia, artichoke, chamomile, eucalyptus, lemon, rosemary, bituminous and the like.

Examples of the peptide or derivative thereof include keratin-degrading peptide, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, succinylated atelocollagen, gelatin, elastin, elastin-degrading peptide, collagen-degrading peptide, hydrolyzed collagen, hydroxypropylammonium chloride Hydrolyzed collagen, elastin degrading peptide, conchiolin degrading peptide, hydrolyzed conchiolin, silk proteolytic peptide, hydrolyzed silk, lauroyl hydrolyzed silk sodium, soy proteolytic peptide, hydrolyzed soy protein, wheat protein, wheat proteolytic peptide, hydrolyzed Degraded wheat protein, casein-degrading peptide, acylated peptide (palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl tetrapeptide Etc.) and the like. Among them, one kind selected from keratin degrading peptide, hydrolyzed keratin, fish-derived collagen elastin, elastin degrading peptide, collagen degrading peptide, hydrolyzed collagen, elastin degrading peptide, hydrolyzed silk, soy proteolytic peptide, hydrolyzed soy protein or The combination with 2 or more types is more preferable.

Examples of the amino acids or derivatives thereof include betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamic acid, glutamine, asparagine, aspartic acid, cysteine, Cystine, methionine, leucine, isoleucine, valine, histidine, threonine, tyrosine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, creatine, epsilon aminocaproic acid, tryptophan, ornithine, N-stearoyl- Sodium L-glutamate, dilauroylglutamate lysine and its salts, lauroylglutamate di (phytosteryl / octyldodecyl), lauroylgue Glutamic acid di (octyldodecyl / phytosteryl / behenyl), and the like. These amino acids or derivatives thereof may be solvates such as hydrates, and may be any of d-form, l-form, and dl-form. Of these, one or more selected from l-form amino acids or derivatives thereof are preferred.

Examples of the washing component include soaps selected from alkali metal salts such as potassium laurate, potassium myristate, potassium palmitate or potassium stearate, alkanolamide salts or amino acid salts; cocoyl glutamate, cocoyl methyl taurine Na Amino acid surfactants such as cocoyl methyl taurine taurine salt, cocoyl glycine salt, stearoyl glutamate and myristoyl glutamate; ether sulfate esters such as laureth sulfate Na; ether carboxylates such as lauryl ether acetate Na; alkylsulfosuccinic acid Sulfosuccinic acid ester salts such as ester Na; fatty acid alkanolamides such as coconut oil fatty acid monoethanolamide and coconut oil fatty acid diethanolamide; sodium lauryl phosphate, polio Monoalkyl phosphate salts such as sodium ethylene lauryl ether phosphate; coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine, lauryldimethylaminoacetic acid betaine, 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, Betaine-type amphoteric surfactants such as lauryl hydroxysulfobetaine and lauroylamidoethylhydroxyethylcarboxymethylbetaine hydroxypropyl sodium phosphate; amino acid-type amphoteric surfactants such as sodium laurylaminopropionate; polyoxyethylene monolaurate (80) Examples include sorbitan surfactants such as sorbitan. Examples of the salt include salts of mineral acids such as sulfuric acid, hydrochloric acid or phosphoric acid, salts of organic acids such as maleic acid, alkali metal salts such as sodium or potassium, alkaline earth metal salts, zinc, copper, ammonium salts, Examples thereof include basic amino acid salts and amine salts such as triethanolamine. Preferably, it is preferably selected from alkali metal salts, alkaline earth metal salts, amine salts, zinc, and copper, and sodium, potassium, triethanolamine salts, zinc, and copper are more preferable.

Examples of the keratin soft component include lanolin, lactic acid, salicylic acid, gluconic acid, glycolic acid, citric acid, malic acid, fruit acid, phytic acid, urea, sulfur, tartaric acid, ferulic acid and the like. Of these, lactic acid, sodium lactate, glycolic acid, salicylic acid, phytic acid, and citric acid are preferable.

Examples of the cell activating component include components derived from plants (for example, bilberry, soybean, lemongrass, aloe vera, chlorella, higi, yakuinin, chamomile, docami, hop, carrot, etc.); royal jelly, royal jelly extract; whey, Components derived from whey extracts such as yogurt extract, hydrolyzed milk protein, yeast extract, etc., amino acids such as γ-aminobutyric acid; retinol, thiamine, riboflavin, pyridoxine hydrochloride, pantothenic acid, pyrroloquinoline quinones, etc. Vitamins; α-hydroxy acids such as glycolic acid and lactic acid; tannins, flavonoids, saponins, allantoin, placenta, proteoglycans, photosensitizer 301 and the like.

Examples of the anti-aging component include hydrolyzed soy protein, retinoid (retinol and derivatives thereof, retinoic acid, retinal acetate, retinol acetate, retinol palmitate, etc.), pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivative, silicon , Silicic acid, N-methyl-L-serine, mevalonolactone, peptides (caprooil tetrapeptide-3, oligopeptide-24, etc.), plants (artichoke, Izayoi rose, seaweed, bilberry, birch, psyllium, crested eel, ogon) , Components derived from Hypericum, Comfrey, Neem, Novara, Giant Giant, Himefuuro, Bodaige, Buttonpi) and the like. Among them, hydrolyzed soy protein, retinol, retinol acetate, retinol palmitate, caprooil tetrapeptide-3, oligopeptide-24, artichoke leaf extract, seaweed extract, bilberry leaf extract, comfrey leaf extract, neem leaf extract, himefuuro Extracts are preferred.

Examples of the anti-glycation component include budreja axillaris leaf extract, ume fruit extract, edelweiss extract, ginkgo biloba extract, cherry leaf extract, pomegranate extract, plantain extract, hawthorn extract, peony extract, bilberry extract, bilberry leaf extract , Green tea extract, black tea extract, horse chestnut extract, Roman chamomile extract, mugwort extract and other plant extracts, evening primrose oil, Amla fruit, fruit juice or extracts thereof, L-arginine, L-lysine, hydrolyzed casein, hydrolyzable Tannin, carnosine and the like can be mentioned.

Examples of the above-mentioned blood circulation promoting component include plants (for example, ginseng, ashitaba, arnica, ginkgo, fennel, enmelio, dutch oak, chamomile, roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake, ginger, hawthorn, and prunus , Cucumber, assembly, thyme, clove, chimpi, capsicum, touki, tonin, spruce, carrot, garlic, butcher bloom, grapes, buttons, maronier, melissa, yuzu, yakuinin, ryokucha, rosemary, rosehip, chimpi, touki, Spruce, peach, apricot, walnut, corn, etc.): caffeine, chili pepper tincture, gamma oryzanol, capsaicin, acetylcholine, ictamol, cantalis tincture Gamma oryzanol, cepharanthine, tolazoline, tocopherol nicotinate, tocopherol acetate, hesperidin and the like.

Examples of the whitening component include vitamin Cs such as tocopherol, tranexamic acid, ascorbic acid and salts thereof, ascorbic acid derivatives (sodium ascorbyl phosphate, magnesium ascorbate phosphate, ascorbyl tetra-2-hexyldecanoate, 2 -O-ethylascorbic acid, 3-O-ethylascorbic acid, ascorbic acid glucoside, etc.), arbutin, kojic acid, placenta, ellagic acid, nicotinamide, hydroquinone, 4-methoxysalicylic acid potassium salt, linoleic acid and its derivatives, Batyl alcohol, plants (eg, Iris (Iris), almonds, aloe, acerola, oolong tea, Ages, Ogon, Ouren, Hypericum, Hypericum, Seaweed, Cuckoo, Gardenia, Kujin, Cucumber Rera, rice, rice haiga, oryzanol, rice bran, saishin, salamander, perilla, peonies, senkyu, sakuhakuhi, soybeans, natto, tea, touki, kansen, hamamelis, safflower, buttonpi, juniper, asenyaku, kiwi, black bean, gentian, Genjin, sage, radish, azalea, parsley, holly, hop, thyme, clove, chimpi, licorice, chamomile, prunes, spirea, purple, lily, grave fruit, genus, lemon, kiwi, pine, neem, artichoke, horsetail, oat , Components derived from Japanese pine evening rush, bilberry, himefuuro, akatsukisou, white willow, yukinoshita, camellia, rosemary, lavender, sanshuyu, etc.). Of these, a combination of one or more selected from ascorbic acid, ascorbic acid glucoside, 3-O-ethylascorbic acid, ascorbyl tetra-2-hexyldecanoate, arbutin, kojic acid, placenta, and nicotinamide is more preferable.

Examples of the decongestant include α-adrenergic agonists, specifically, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride, methylephedrine hydrochloride, epinephrine hydrogen tartrate, nitrate And naphazoline. These may be d-form, l-form or dl-form.

Examples of the eye muscle modulator component include cholinesterase inhibitors having an active center similar to acetylcholine, specifically, neostigmine methyl sulfate, tropicamide, atropine sulfate helenien and the like.

Examples of the antihistamine component or antiallergic agent component include salts such as acitazanolast, diphenhydramine or its hydrochloride, chlorpheniramine maleate, ketotifen fumarate, levocabastine or its hydrochloride, amlexanox, ibudilast, etc. , Sodium tazanomoglycate, potassium pemirolast, and the like.

Examples of the above polyphenols include flavonoid polyphenols such as curcuminoids, flavanones, stilpenoids, polymethoxyflavonoids, flavonols, xanthonoids, chalcones, lignoids, flavanols, isoflavones, and phenolic polyphenols. Of these, curcuminoid, hesperidin, resveratrol, nobiletin, rutin, quercetin, mandiferin, carthamin, lignan, catechin, isoflavone, anthocyanin, tannin, cacao mass polyphenol, and chlorogenic acid are particularly preferable.

(PH)
The pH of the various compositions and various agents of the present invention is usually pH 2.0 to 9.0, preferably pH 3 to 8.5, more preferably pH 3.5 to 8.0, More preferably, the pH is 4.0 to 7.5. This pH can be adjusted by using a pH adjuster.

(Manufacturing methods of various compositions and various agents)
The production method of the various compositions and various agents of the present invention is not particularly limited, and the devil's claw extract of the present invention, which is an essential component, the other components blended as necessary, various compositions or various agents. The base or carrier necessary for production, additives, etc. can be appropriately selected and blended, and produced by a conventional method.

The above-mentioned various compositions and various agents of the present invention comprise the essential components and the other components described above as a base or carrier usually used in cosmetics, pharmaceuticals, quasi drugs, foods, and the like. Accordingly, it can be mixed according to a conventional method together with additives to be described later, and emulsified or solubilized as necessary to obtain various external preparation compositions.

Examples of the base or carrier include liquid paraffin, isoparaffin, hard fat, microcrystalline wax, polybutene, polyethylene powder, squalane, petrolatum, gelled hydrocarbon (such as plastibase), ozokerite, α-olefin oligomer, and light liquid paraffin. Hydrocarbons such as methylpolysiloxane, highly polymerized methylpolysiloxane, cyclic silicone, alkyl-modified silicone, amino-modified silicone, polyether-modified silicone, polyglycerin-modified silicone, silicone / alkyl chain co-modified polyether-modified silicone, and cross-linkable silicone , Silicone / alkyl chain co-modified polyglycerin modified silicone, polyether modified branched silicone, polyglycerin modified branched silicone, acrylic silicone, pheny Silicone oils such as modified silicone and silicone resin; palm oil, olive oil, rice bran oil, shea butter, avocado oil, linseed oil, camellia oil, macadamia nut oil, corn oil, safflower oil, kyounin oil, cinnamon oil, grape seed oil, Sunflower oil, almond oil, sasanqua oil, rapeseed oil, sesame oil, cocoa butter, hydrogenated coconut oil, palm oil, palm kernel oil, owl kernel oil, owl, wheat germ oil, rice germ oil, cottonseed oil, soybean oil, peanut oil, Fats and oils such as tea seed oil, evening primrose oil, cucumber nut oil, hazelnut oil; waxes such as jojoba oil, miw wax, candelilla wax, rice bran wax, cotton wax, carnauba wax, lanolin or lanolin derivatives; cetanol, cetostearyl alcohol, stearyl alcohol, Behenyl alcohol, octyldodecanol, Higher alcohols such as isostearyl alcohol, phytosterol and cholesterol; higher fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, isostearic acid and 12-hydroxystearic acid; ethyl cellulose, hydroxypropyl Cellulose derivatives such as cellulose and hydroxypropylmethylcellulose; polyvinyl pyrrolidone; carrageenan; polyvinyl butyrate; polyethylene glycol; dioxane; butylene glycol adipate polyester; diisopropyl adipate, isopropyl myristate, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate , Isononyl isononanoate, pentaerythritol tetra-2-ethylhexanoate, etc. Esters; polysaccharides such as dextrin and maltodextrin; vinyl polymers such as carboxyvinyl polymer and alkyl-modified carboxyvinyl polymer; lower alcohols such as ethanol and isopropanol; ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol mono Glycol ethers such as propyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monopropyl ether, diethylene glycol monobutyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, dipropylene glycol monoethyl ether, dipropylene glycol monopropyl ether ; Water etc. It is. The bases or carriers described above may be used alone or in combination of two or more. Further, the amount used thereof is appropriately selected from a range known to those skilled in the art.

In the various compositions and various agents of the present invention, known additives that are added to cosmetics, pharmaceuticals, quasi drugs, foods, etc., as long as the effects of the present invention are not impaired, for example, surfactants, stabilization Agent, buffer, tonicity agent, antioxidant, colorant, pearl luster imparting agent, dispersant, chelating agent, pH adjuster, preservative, thickener, irritation reducing agent, excipient, lubricant, Additives such as binders, disintegrants, solvents, fats and oils, emulsifiers, dispersants, suspending agents, stabilizers, thickeners, sweeteners, colorants, fragrances, antioxidants, acidulants, fruit juices, etc. Can be added. These additives may be used alone or in combination of two or more.

The surfactant may be any of a nonionic surfactant, a cationic surfactant, an anionic surfactant, an amphoteric surfactant, and the like. For example, sorbitan monoisostearate, sorbitan monolaurate Sorbitan monopalmitate, sorbitan monostearate, sorbitan fatty acid esters such as diglycerol sorbitan penta-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate; propylene glycol fatty acid esters such as propylene glycol monostearate; Cured castor such as polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene hydrogenated castor oil 60 (HCO-60), polyoxyethylene hydrogenated castor oil 80, etc. Oil derivatives: polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan monooleate (polysorbate 80), isostearic acid Polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene (20) sorbitan; polyoxyethylene monococonut oil fatty acid glyceryl; glycerin alkyl ether; alkyl glucoside; polyoxyalkylene alkyl ether such as polyoxyethylene cetyl ether; stearylamine, oleylamine Amines such as polyoxyethylene / methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, PEG- Silicone surfactants such as poly dimethicone and the like.

Examples of the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, butylhydroxyanisole, trometamol, sodium formaldehyde sulfoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, monostearin. Acid glycerin etc. are mentioned.

Examples of the buffer include citrate buffer, acetate buffer, carbonate buffer, borate buffer, phosphate buffer, and the like. Specifically, citric acid, sodium citrate, acetic acid, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, boric acid, borax, phosphoric acid, disodium hydrogen phosphate, sodium dihydrogen phosphate, phosphoric acid A potassium dihydrogen etc. are mentioned.

Examples of the isotonic agent include sodium bisulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, and phosphoric acid. Examples thereof include disodium hydrogen, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glycerin, and propylene glycol.

Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, sorbic acid, sodium sulfite, ascorbic acid, sodium ascorbate, ascorbic acid stearate, ascorbic acid sodium stearate, ascorbyl palmitate, tocopherol, Tocopherol acetate, tocotrienol, bisulfite, sodium hyposulfite, sulfur dioxide, disodium calcium EDTA, erythorbic acid, sodium erythorbate, L-cysteine hydrochloride, ubiquinones such as coenzyme Q10, lignans such as sesamin, curcumin, capsaicin, Such as gingerol, resveratrol, anthocyanin, cyanidin, bilberry extract and their analogs or derivatives It is below. Among them, dibutylhydroxytoluene, ascorbic acid, ascorbyl palmitate, tocopherol, tocopherol acetate, coenzyme Q10, resveratrol, anthocyanin, sesamin, curcumin, capsaicin, gingerol, and bilberry extract are preferable.

Examples of the colorant include inorganic pigments and natural pigments.

Examples of the pearl luster imparting agent include ethylene glycol distearate, ethylene glycol monostearate, and triethylene glycol distearate.

Examples of the dispersant include sodium pyrophosphate, sodium hexametaphosphate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl vinyl ether / maleic anhydride crosslinked copolymer, and organic acid.

Examples of the chelating agent include EDTA · disodium salt, EDTA · calcium disodium salt, ascorbic acid and the like.

Examples of the pH adjuster include inorganic acids (phosphoric acid, hydrochloric acid, sulfuric acid, etc.), organic acids (lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, sodium succinate, gluconic acid, sodium malate, etc.) Potassium carbonate, sodium hydrogen carbonate, carbon dioxide, inorganic bases (potassium hydroxide, sodium hydroxide, etc.), organic bases (triethanolamine, diisopropanolamine, triisopropanolamine, etc.).

Examples of the preservative include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, and paraoxybenzoic acid. Benzyl, methyl paraoxybenzoate, phenoxyethanol, chlorobutanol, benzyl alcohol, phenethyl alcohol, sorbic acid, thymol, isopropylmethylphenol, capryl hydroxamic acid, methylisothiazoline, butylcarbamate propynyl iodide, 1,3-propanediol, 1, Examples thereof include 2-pentanediol, 1,2-hexanediol, 1,2-octanediol or a salt thereof.

As the thickener, for example, vinyl thickeners such as polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, Cellulose thickeners such as hydrophobized hydroxypropylmethylcellulose, guar gum, pectin, pullulan, gelatin, locust bean gum, carrageenan, agar, glucomannan, curdlan, gellan gum, sclerotium gum, xanthan gum, alkyl methacrylate methacrylate Polymer, polyethylene glycol, bentonite, alginic acid, propylene alginate Glycol, macrogol, sodium chondroitin sulfate, hyaluronic acid, sodium hyaluronate, (hydroxyethyl acrylate / acryloyl dimethyl taurine Na) copolymer, and (ammonium acryloyldimethyltaurate / vinyl pyrrolidone) copolymers and the like.

Examples of the irritation reducing agent include cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, acrylic polymer, gelatin, gum arabic, pullulan, pregelatinized starch, agar, Examples include tragacanth, sodium alginate, propylene glycol alginate, licorice extract, and 2-methacryloyloxyethyl phosphorylcholine.

Examples of the excipient include lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and oxalic acid.

Examples of the binder include purified sucrose, glucose, trehalose, lactose, maltose, sodium saccharin, aspartame, acesulfame potassium, maltodextrin, corn starch, potato starch, wheat starch and pregelatinized starch thereof, mannitol, sorbitol, xylitol Sugar alcohol such as erythritol and sucralose, cellulose such as crystalline cellulose, methylcellulose, ethylcellulose, hypromellose, hydroxypropylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, carboxymethylcellulose calcium, carmellose calcium, hypromellose phthalate, cellulose acetate phthalate Polymer, calcium phosphate, Polyvinyl pyrrolidone. Among these, crystalline cellulose, potato starch, and maltodextrin are preferable.

Examples of the disintegrant include starch, low-substituted hydroxypropylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, hydroxypropyl starch, partially pregelatinized starch, sodium alginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate. , Stearic acid monoglyceride, lactose and the like.

Examples of the lubricant include stearic acid, magnesium stearate, calcium stearate, polyoxyl stearate, cetanol, talc, hydrogenated oil, sucrose fatty acid ester, dimethylpolysiloxane, beeswax, white beeswax, borax, polyethylene glycol and the like. It is done.

The oils include palm oil, palm kernel oil, palm oil, corn oil, sunflower oil, safflower oil, peanut oil, cocoa butter, cottonseed oil, soybean oil, rapeseed oil, rice oil, rice germ oil, perilla oil, linseed oil Natural vegetable oils such as beef tallow, milk fat, pork tallow, cacao butter, fish oil, whale oil, butter, butter oil, etc., and these hardened oils, fatty acid (including medium chain fatty acids) glycerides (glycerides, diglycerides, triglycerides) Etc.) and beeswah. Of these, beeswax is preferred.

Examples of the emulsifier, dispersant, suspending agent and stabilizer include polyhydric alcohols such as polyethylene glycol, propylene glycol, glycerin and sorbitol; synthetic emulsifiers such as glycerin fatty acid ester, sucrose fatty acid ester, and polyglycerin fatty acid ester. Natural emulsifiers such as lecithins, saponins, plant sterols, milk fat globule membranes; sodium carboxymethylcellulose, kaolin, xanthan gum, methylcellulose, tragacanth and the like.

Examples of the sweetener include sucrose, fructose, maltose, trehalose, licorice extract, saccharin, saccharin sodium, sucralose, stevia processed sweetener, rakanka extract, aspartame, acesulfame potassium, erythritol, sorbitol, xylitol, maltitol, reduced starch syrup And reduced maltose starch syrup.

As the sour agent, adipic acid, itaconic acid, citric acid, potassium citrate, glucono delta lactone, gluconic acid, succinic acid, sodium succinate, sodium acetate, tartaric acid, sodium tartrate, carbon dioxide, lactic acid, sodium lactate, Examples include glacial acetic acid, phytic acid, fumaric acid, sodium fumarate, malic acid, and phosphoric acid.

Examples of the juice include lemon juice, orange juice, berry juice, apple juice, and banana juice.

(Formulation)
The forms of the various compositions and various agents of the present invention are not particularly limited. For example, ointments, solutions, suspensions, emulsifiers (milky lotions and creams), gels, liniments, lotions, patches, mists, Foams, aerosols, sticks, powders, granules, tablets (including uncoated tablets, sugar-coated tablets, intraoral quick disintegrating tablets, chewable tablets, effervescent tablets, troches, film-coated tablets, etc.), detergents, soaps, solid preparations , Capsules, films, confectionery (including candy, gummi, nougat, etc.), syrups, drinks, juices, soft drinks, tea and other liquid foods, biscuits, tablets, granule powders, powders, capsules, etc. Solids, pastes, jellies, soups, seasonings, semi-fluid forms such as dressings. These preparations can be produced according to a conventional method, for example, the method described in the 17th revised Japanese Pharmacopoeia General Rules for Preparations.

Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.

[Test 1] Production of Devil's Claw Extract The devil's claw extract of the present invention was obtained by the following production method. This production method is composed of an ethanol extraction step of a devil's claw dry powder, a purification and pulverization step of the extract, and a powder re-dissolution step. First, the devil's claw dry powder as a raw material was subjected to heat extraction with a 50% (w / w) ethanol aqueous solution to obtain an extract. The obtained extract was subjected to activated carbon treatment, followed by filtration and column purification. In the column purification, a hydrophobic resin column was used, and a hydrophobic component was removed from the extract to obtain a purified extract. Next, dry powder was obtained from this purified extract by spray drying (Production Examples 1 to 4). The obtained dry powder or, if necessary, dissolved in 1,3-BG aqueous solution was used in the following tests.

[Test 2] Quantification of Harpagoside (harpagoside) About 4 lots of dried powder of the devil's claw extract of the present invention obtained in Test 1 (manufactured on an actual production scale (Production Examples 1 to 4)) and 4 kinds of conventional products, Harpagoside was quantified. Specifically, each sample was weighed, dissolved in purified water, filtered with an aqueous 0.45 μm filter (GL Science), and used as a test sample. Harpagoside was quantified based on a calibration curve of a Harpagoside preparation (SIGMA). Analysis was performed using HPLC (Agilent HPLC 1200) under the following conditions. The results are shown in Table 1. “ND” in the table indicates that it was below the detection limit.
UV absorption photometer 288nm,
Column: Inertsil ODS 2 (5 um, 4.6 mm * 150 mm),
Mobile phase: 23% MeCN: 77% MiliQ water,
Column temperature 40 ° C,
Flow rate 1.0 mL / min,
Analysis cycle 30min,
Injection 20 uL

As shown in Table 1 above, the four conventional products contain Harpagoside at a high concentration exceeding 1.0%, whereas the four lots according to the present invention have 0.048%, 0.003 % Or below the detection limit, which was a very low concentration compared to the conventional product.

[Test 3] Quantification of polyphenols Quantification of polyphenols for 4 lots of dried powder of the devil's claw extract of the present invention obtained in Test 1 (manufactured on an actual production scale (Production Examples 1 to 4)) and 4 conventional products Went. Specifically, 0.2 g of each sample was weighed, 50% ethanol was added, extraction was performed by ultrasonic irradiation for 30 minutes, and then the volume was adjusted to 100 mL. After centrifugation, the supernatant was filtered with a filter to obtain a sample for measurement. To 1 mL of the sample, 0.5 mL of 2-fold diluted Folin-Ciocalteu reagent (Merck Co., Ltd.) and 5 mL of 0.4 mol / L sodium carbonate aqueous solution were added and left at 30 ° C. for 30 minutes. The absorbance of the supernatant after centrifugation was measured using a UV-visible spectrophotometer (V-630: JASCO Corporation) at a measurement wavelength of 660 nm. The polyphenol was quantified based on a calibration curve of a sample of (+)-catechin hydrate (Tokyo Chemical Industry Co., Ltd.). The results are shown in Table 2.

As shown in Table 2 above, the 4 types of conventional products contain polyphenols at a high concentration exceeding 3.0%, whereas the 4 lots of the present invention have extremely low concentrations compared to the conventional products. Met.

[Test 4] Coloring evaluation test Coloring evaluation was performed on 4 lots of dried powder of the devil's claw extract of the present invention obtained in Test 1 (manufactured on an actual production scale) and 4 types of conventional products. Specifically, the amount of coloring was evaluated using an absorptiometer. As a measurement sample, the dry powder used in Test Example 1 was used. Specifically, 100 mg of each dry powder was weighed and suspended and dissolved in 20 mL purified water (0.5%). Absorbance at 400-500 nm was measured with a spectrophotometer or a photoelectric photometer UV-2450 (manufactured by Shimadzu Corporation). Purified water was used as a blank. The results are shown in FIGS. In addition, by visual inspection, the dry powder solution of the four conventional devil's claw extracts has a brown to brown color, whereas the solution of four lots of the devil's claw extract dry powder of the present invention is almost colorless. It was confirmed that there was (FIG. 3).

As shown in FIGS. 1 and 2, the dry powder solution of the four conventional devil's claw extracts has a high degree of coloration, whereas the solution of four lots of the dry powder of the devil's claw extract of the present invention is colored. The degree was found to be significantly lower. It was also correlated with the visual result (FIG. 3). As described above, the devil's claw extract of the present invention can be blended in a preparation without impairing the appearance, and it has been clarified that it is excellent as a preparation raw material.

[Test 5] Color Change Evaluation Test The thermal stability of the raw material is important in ensuring the quality of the product. In addition, the color change of the product can be an indicator of quality deterioration. Therefore, in order to evaluate the stability of the devil's claw extract blended in the product, the amount of color change of the devil's claw extract stored under high temperature conditions was confirmed. Specifically, 100 mg of each dry powder of the Devil's Claw extract of the present invention obtained in Test 1 (Production Examples 1 to 4) and 4 conventional products was weighed, suspended and dissolved in 20 mL purified water. (0.5% (w / v)). It was stored in a thermostat set at 60 ° C. for 1 week, taken out after 1 week, and the absorbance at 400-500 nm was measured with a spectrophotometer or photoelectric photometer UV-2450 (manufactured by Shimadzu Corporation), and the area value was calculated. Purified water was used as a blank. The results are shown in FIG.

As shown in FIG. 4, it was found that the aqueous solution of the devil's claw extract of the present invention (Production Examples 1 to 4) had a small amount of color change compared to the aqueous solutions of the four conventional devil's claw extracts. That is, since the devil's claw extract of the present invention is unlikely to undergo discoloration during storage, it is possible to extend the storage period as a raw material, and thus it has been clarified that it is excellent as a raw material.

[Test 6] Permeability evaluation test The solubility of the raw material in water is important in ensuring the quality of the product from the viewpoint of precipitation in the preparation. Therefore, the solubility of the raw material in water was evaluated using the transmittance of a sample (5% (w / w)) in which the raw material was suspended and dissolved in purified water. Samples obtained by suspending and dissolving the dried powder of the four conventional devils claw extracts and the devils claw extract of the present invention (Production Examples 1 to 4) in purified water, respectively, have a transparent or translucent appearance. It was. The transmittance is measured by the 17th revised Japanese Pharmacopoeia [B] General Test Method. Physical test method Spectroscopic measurement method 2.24 It carried out by the method according to the method as described in the ultraviolet visible absorbance measurement method. In the present specification, the solubility of the raw materials was determined as follows. That is, an aqueous solution (or a water suspension) of the raw material is converted into a water transmittance as a transmittance at a wavelength of 700 nm using a spectrophotometer or a photoelectric photometer UV-2450 (manufactured by Shimadzu Corporation) by an ultraviolet-visible absorbance measurement method. When the content is in the range of 85 to 100%, preferably 90 to 100%, the transmittance is judged to be high and the solubility in water is excellent. The results are shown in FIG.

As shown in FIG. 5, it was found that the aqueous solutions of the four conventional devil's claw extracts have very low transmittance when compared at the same concentration as the aqueous solution of the devil's claw extract of the present invention. . That is, it has been found that the conventional devil's claw extract causes turbidity and precipitation when dissolved in water. On the other hand, it became clear that even when the devil's claw extract of the present invention was dissolved in water, turbidity and precipitation did not occur, and it was difficult to cause deterioration in product quality.

[Test 7] Odor test Although the odor has a great influence on the evaluation of the product, it has been known that the conventional devil's claw extract gives off a specific odor when dissolved in water. An odor sensory test was conducted on 4 lots of dried powder of the devil's claw extract of the present invention (manufactured on an actual production scale (Production Examples 1 to 4)) and 4 conventional products. Specifically, 5.0 g of each dry powder was suspended and dissolved in 95 mL of purified water (5% (w / w)). Each sample was dispensed into a 10 mL glass vial and stored at 60 ° C. for 1 week, and then each odor was confirmed by a sensory test. The sensory test was conducted by three healthy men and women in their 20s and 30s. Subjects were asked to fill out a questionnaire, and the odor was quantified by comparing purified water (left) and each sample (right). The odor was digitized as follows. The result of averaging the numerical values of the subjects in each sample is shown in FIG.

Left is very odor: -3 points Left is odor: -2 points Left is slightly odor: -1 point Same: 0 points Right is slightly odor: 1 point Right is odor: 2 points Right is very odor: 3 points

As shown in FIG. 6, it was found that the devils claw extract samples of the four conventional products had a strong odor compared to the devils claw extract sample of the present invention. The sample of the devil's claw extract of the present invention has a value almost similar to that of purified water, and has been found to have almost no odor. Thus, since the devil's claw extract of this invention has few odors compared with a conventional product, it can be mix | blended with various kinds of products, and is preferable.

[Test 8] Melanin synthase gene expression analysis In order to confirm the effectiveness of the devil's claw extract of the present invention obtained in Test 1 in whitening, melanin synthase (three types of melanin synthesis in melanocytes) was confirmed. The effects on the expression of enzymes (TYR, TYRP1, DCT) were analyzed at the gene level. NHEM (human normal epidermal melanocyte AD) (KURABO, KM-4109) was inoculated at a density of 1 × 10 ⁵ cells / 2 mL / well on a 6-well plate and cultured at 37 ° C. under 5% CO ₂ conditions. After 72 hours, the culture solution was removed, and 2 mL of a medium containing the product of the present invention at concentrations of 0.1%, 0.5%, and 1.0% was added and further cultured. After culturing for a certain time, RNA was recovered using Buffer RLT (QIAGEN). The crudely extracted RNA was subjected to column purification using RNeasy Mini Kit (Qiagen). The total RNA concentration was measured using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). A reverse transcription reaction solution was prepared, and reverse transcription reaction of RNA was performed using Applied Biosystems (trademark) Thermal Cycler (Thermo Fisher Scientific). Real-time PCR reactions were performed using the Premix Ex Taq ™ kit (TaKaRa) and Quant Studio 7 Flex Real-Time PCR System (Thermo Fisher Scientific). The maximum number of PCR reactions was 50 cycles. The gene expression level is calculated as 2 ^ -ΔΔCT value from the number of cycles (threshold cycle value: Ct value) resulting in a constant amount of amplification product obtained by real-time PCR. Comparison was made using the relative value when 1.00. PCR primers for each gene were recommended primers commercially available from Thermo Fisher Scientific. The results are shown in FIGS.

The gene expression of three melanin synthesis-related enzymes in NHEM was suppressed by the devil's claw extract of the present invention. Moreover, as a result of analyzing over time about DCT with the largest suppression level, the DCT expression suppression effect of the devil's claw extract of this invention was confirmed in any time point. From the above, it was suggested that the devil's claw extract of the present invention may be a whitening material that suppresses the expression of melanin synthase.

[Test 9] Collagen production test Wrinkles and sagging of the devil's claw extract of the present invention (Production Example 5) obtained by the production method of Test 1 and each component (stachyose, sucrose, raffinose) contained in the devil's claw extract of the present invention In order to confirm the effectiveness in the above, the effect on collagen production in normal human dermal fibroblasts (NHDF) was examined by ELISA. NHDF is cultured in the devil's claw extract of the present invention (Production Example 5) or a medium to which the above components are added, and the amount of collagen precursor produced in the medium is determined using Human Pro-Collagen I alpha 1 DuoSet ELISA (R & D). And evaluated as an index of collagen production. The results are shown in FIGS.

A remarkable collagen production promoting action was confirmed by the devil's claw extract (1%) of the present invention. In addition, although not reaching the level of the present invention, any active ingredient (stachyose, sucrose, raffinose) was confirmed to have a concentration-dependent collagen production promoting action. It was suggested that the effect confirmed with the devil's claw extract (1%) of the present invention was a combination of the effects of these active ingredients. From the above, it was suggested that the devil's claw extract of the present invention may be an anti-wrinkle and anti-aging material exhibiting an excellent effect on wrinkles and sagging.

[Test 10] Elastin fiber formation test In order to confirm the effectiveness of the devil's claw extract of the present invention of Production Example 3 obtained in Test 1 in wrinkles and sagging, elastin fibers by normal human skin fibroblasts (NHDF) The effect on formation was examined by immunostaining. NHDF was cultured in a medium supplemented with the devil's claw extract of the present invention (Production Example 3), and elastin fiber formation was evaluated by immunostaining. The results are shown in FIG.

It was confirmed that elastin fibril formation occurred by the addition of 2% FBS serving as a scaffold, and that the fibril formation was further promoted by culturing in a medium supplemented with the devil's claw extract of the present invention at a concentration of 0.05%. did. From the above, it was suggested that the devil's claw extract of the present invention may be an anti-wrinkle and anti-aging material that has an effect on wrinkles and sagging.

[Test 11] Hyaluronic acid production test -1
Using rabbit-derived cartilage cultured cells (obtained from the primary cell), in a hyaluronic acid production test, the usefulness evaluation of the product of the present invention (Production Example 4) obtained in Test 1 as an external preparation and oral or food material was performed. It was.

Specifically, rabbit-derived cartilage cultured cells were three-dimensionally cultured in a 1.5 mL microtube. At that time, a differentiation medium containing no addition product of the present invention (final concentrations of 0.1, 1, 10 mg / mL) and a differentiation medium without addition were used as culture media. The medium was changed every 5-7 days. The culture was performed for 18 days, and the final medium change was performed one week before the collection date. The culture broth was collected, and the amount of hyaluronic acid secreted into the culture broth was quantified by an enzyme-linked immunoassay (Hyaluran Quantikine ELISA Kit; manufactured by R & D). The results are shown in FIG.

As shown in FIG. 16, it was found that the amount of hyaluronic acid produced in chondrocytes was greatly improved by adding 10 mg / mL of the product of the present invention. That is, one of the causes of joint pain associated with aging is a decrease in joint components such as hyaluronic acid, but the effect of improving arthropathy is expected by taking the product of the present invention.

[Test 12] Hyaluronic acid production test-2
Usefulness of the product of the present invention (Production Example 4) obtained in Test 1 as an external preparation and oral or food material in a hyaluronic acid production test using normal human skin fibroblasts (NHDF) (obtained from KURABO) Evaluation was performed.

Specifically, NHDF was cultured for 48 hours in a medium to which the devil's claw extract of the present invention (Production Example 4) or the positive control N-acetylglucosamine (Wako) was added, and the amount of hyaluronic acid produced in the medium was determined. It measured by Hyaluronan Quantikine ELISA Kit (made by R & D). After collecting the medium, the medium was replaced with a medium supplemented with Hoechst 33342 (DOJINDO), cultured at 37 ° C. under 5% CO _{2 for} 30 minutes, and the stained nuclei were counted and used as an indicator of cell viability. The amount of hyaluronic acid produced per cell was evaluated by dividing the amount of hyaluronic acid by the cell viability. The results are shown in FIG.

As shown in FIG. 17, it was found that the amount of hyaluronic acid produced in normal human skin fibroblasts was significantly improved by adding the devil's claw extract (0.5%) of the present invention. That is, one of the causes of skin wrinkles and sagging with aging is a decrease in hyaluronic acid, but the effect of improving these symptoms is expected by ingesting the product of the present invention, and it is effective for wrinkles and sagging. The possibility of becoming an anti-wrinkle and anti-aging material is suggested.

[Test 13] Gobi Kosa Dust (GKD) -induced inflammation test-1
Using the normal human epidermal cells (NHEK) (obtained from KURABO), the product of the present invention (manufacturing) obtained in Test 1 as an external preparation and oral or food material against inflammation induced by GKD which is a causative agent of air pollution The usefulness of Example 4) was evaluated.

Specifically, NHEK was cultured for 24 hours in a medium supplemented with the Devil's Claw extract of the present invention (Production Example 4) and GKD, and the RNA of NHEK was collected, and the expression levels of IL-8 and IL-6 genes were measured in real time. Analysis was performed by PCR reaction.

As shown in FIG. 18, IL-8 and IL-, which are inflammatory cytokines induced by GKD in normal human epidermal cells, by adding the devil's claw extract of the present invention (1.0% and 1.5%). It was found that the expression of 6 was significantly suppressed. That is, the effect of improving skin inflammation associated with GKD exposure by ingesting, applying or washing the product of the present invention was expected.

[Test 14] Gobi Kosa Dust (GKD) -induced inflammation test-2
Using human corneal epithelial cells (HCET) (obtained from RIKEN BRC), external preparations (including skin cosmetics, cleansing agents, etc.) and ophthalmic preparations (eye drops, Efficacy evaluation of the product of the present invention (Production Example 4) obtained in Test 1 as an oral and food material was conducted.

Specifically, HCET was cultured in a medium supplemented with the devil's claw extract of the present invention (Production Example 4) for 1 hour, and then GKD was added. After culturing for 24 hours, HCET RNA was collected, and the gene expression levels of IL-1β, IL-8, and IL-6 were analyzed by real-time PCR reaction.

As shown in FIG. 19, IL-1β, IL-8, and IL-6, which are inflammatory cytokines induced by GKD in human corneal epithelial cells by adding the devil's claw extract (0.5%) of the present invention. Was found to significantly suppress the expression of. That is, the effect of improving eye inflammation and the like accompanying GKD exposure by ingesting the product of the present invention, or by washing and applying the product of the present invention was expected.

Hereinafter, formulation formulation examples of external compositions (cosmetics, quasi drugs, pharmaceuticals) and oral compositions (pharmaceuticals, supplements, drinks, general foods, etc.) containing the devil's claw extract of the present invention are shown.

[External composition]
The numerical values in the table below indicate the concentration (% by weight) of each component.

[Soft capsule]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in each formulation example of a soft capsule.

[tablet]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in each formulation example of a tablet.

[Granule]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in the formulation example of a granule.

[drink]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in the formulation example of a drink.

[jelly]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in each prescription example of jelly.

[Gummy]
The numerical value in the following table | surface has shown the daily intake (mg) of each component in each prescription example of gummy.

[External composition]
The table below shows formulation examples (formulation examples 20 to 33) of the composition for external use. The numerical value in each table | surface has shown the density | concentration (weight%) of each component.

Table 10 below (Tables 10-1 and 10-2) is a formulation example of an external preparation having an anti-pouring action.

Table 11 below is a prescription example of a cleaning agent (foam discharge type).

Table 12 below shows a shampoo prescription example (prescription example 30).

Table 13 below is a cleansing prescription example (prescription example 31).

Table 14 below shows a prescription example (prescription example 32) of the cleaning agent (cream type).

Table 15 below shows a prescription example (prescription example 33) of the eye wash.

The devil's claw extract of the present invention is obtained by removing a hydrophobic substance such as harpagoside known as an active ingredient from the conventional devil's claw extract, and the content of harpagoside is 1.0% by weight or less. It is a novel extract that is remarkably suppressed. Unlike the conventional devil's claw extract, there is an advantage that it is easy to mix in various products because it has excellent stability and high solubility because it does not produce unique coloring, odor and bitterness. In addition, this devil's claw extract of the present invention is a melanin synthase gene expression inhibitory action in skin, collagen production promoting action, elastin fiber formation promoting action, hyaluronic acid production promoting action, an inflammatory substance induced by air pollutants It has a production inhibitory effect and can also be expected to have whitening, anti-wrinkle, anti-aging, arthropathy ameliorating effect, and anti-inflammatory effect (anti-poration). Furthermore, iridoids such as harpagoside have a bitter taste and are known to have various pharmacological effects, and conventional devil's claw extracts may cause inconvenience depending on the administration route, application site, and application target. there were. However, since the devil's claw extract of the present invention has a significantly reduced content of iridoids, the above restriction is unnecessary and the safety is excellent. From the above, the devil's claw extract of the present invention is used as cosmetics, pharmaceuticals, quasi-drugs, foods (functional foods, supplements, drinks, etc.), etc. It can be suitably used as a composition (including a food composition), an ophthalmic composition, and the like.

Claims (10)

1. Devil's claw extract having a harpagoside content of 1.0% by weight or less.
2. The devil's claw extract according to claim 1, wherein the content (% by weight) of harpagoside relative to the content (% by weight) of stachyose is 0 to 1.0.
3. When the devil's claw extract is a dry powder, or when the devil's claw extract is a liquid, when the devil's claw extract is a dry powder, the absorbance at a wavelength in the visible light region of the 0.5 wt. Devil's claw extract according to claim 1 or 2, characterized in that it is 0.1 or less.
4. A composition for inhibiting melanin synthase gene expression, comprising the devil's claw extract according to any one of claims 1 to 3.
5. A whitening composition comprising the devil's claw extract according to any one of claims 1 to 3.
6. A composition for promoting collagen production, comprising the devil's claw extract according to any one of claims 1 to 3.
7. A composition for promoting the formation of elastin fibers, comprising the devil's claw extract according to any one of claims 1 to 3.
8. A composition for promoting hyaluronic acid production, comprising the devil's claw extract according to any one of claims 1 to 3.
9. A composition for enhancing skin barrier function, comprising the devil's claw extract according to any one of claims 1 to 3.
10. An anti-poration composition containing the devil's claw extract according to any one of claims 1 to 3.

Images